Your browser doesn't support javascript.
loading
A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.
Yuan, Ming; Gao, Xuefei; Chard, Louisa S; Ali, Zarah; Ahmed, Jahangir; Li, Yunqing; Liu, Pentao; Lemoine, Nick R; Wang, Yaohe.
Affiliation
  • Yuan M; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , London, UK.
  • Gao X; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus , Cambridge, UK.
  • Chard LS; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , London, UK.
  • Ali Z; The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London , London, UK.
  • Ahmed J; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , London, UK.
  • Li Y; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , London, UK.
  • Liu P; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus , Cambridge, UK.
  • Lemoine NR; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , London, UK ; Sino-British Research Centre for Molecular Oncology, National Center for International Research in Cell and Gene Therapy, Zhengzhou University , Zhengzhou, China.
  • Wang Y; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , London, UK ; Sino-British Research Centre for Molecular Oncology, National Center for International Research in Cell and Gene Therapy, Zhengzhou University , Zhengzhou, China.
Mol Ther Methods Clin Dev ; 2: 15035, 2015.
Article de En | MEDLINE | ID: mdl-26417609
ABSTRACT
The current method for creation of vaccinia virus (VACV) vectors involves using a selection and purification marker, however inclusion of a gene without therapeutic value in the resulting vector is not desirable for clinical use. The Cre-LoxP system has been used to make marker-free Poxviruses, but the efficiency was very low. To obtain a marker-free VACV vector, we developed marker gene excision systems to modify the thymidine kinase (TK) region and N1L regions using Cre-Loxp and Flp-FRET systems respectively. CRISPR-Cas9 system significantly resulted in a high efficiency (~90%) in generation of marker gene-positive TK-mutant VACV vector. The marker gene (RFP) could be excised from the recombinant virus using Cre recombinase. To make a marker-free VV vector with double gene deletions targeting the TK and N1L gene, we constructed a donor repair vector targeting the N1L gene, which can carry a therapeutic gene and the marker (RFP) that could be excised from the recombinant virus using Flp recombinase. The marker-free system developed here can be used to efficiently construct VACV vectors armed with any therapeutic genes in the TK region or N1L region without marker genes. Our marker-free system platform has significant potential for development of new marker-free VACV vectors for clinical application.

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Mol Ther Methods Clin Dev Année: 2015 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Mol Ther Methods Clin Dev Année: 2015 Type de document: Article Pays d'affiliation: Royaume-Uni